Last updated: February 20, 2026
What is the scope of patent EP4616857?
Patent EP4616857 pertains to a pharmaceutical composition or method related to a specific drug compound or combination. It aims to protect the unique aspects of the medicinal preparation, including the formulation, administration, or specific use in treating a medical condition. The scope heavily depends on the claims, which define the legal boundaries of the invention.
The patent's claims are directed toward formulations involving a specific active ingredient, possibly combined with excipients, for treating a defined disease area, such as oncology, neurology, or infectious diseases. The scope includes both the composition and methods of therapeutic application, with potential claims covering dosages, routes of administration, or combination therapies.
How are the claims structured?
Types of claims
- Product Claims: Cover the active pharmaceutical ingredient (API) or specific formulations.
- Method Claims: Cover methods of treatment, manufacturing processes, or use claims.
- Combination Claims: Cover the use of the drug in combination with other compounds or therapies.
Claim language
The claims are constructed with a uniform structure, focusing on:
- The chemical structure or composition.
- Therapeutic or prophylactic use.
- Formulation specifics (e.g., dosage forms, release profiles).
- Applications to particular diseases or conditions.
Claim breadth and limitations
The scope's breadth hinges on how narrowly or broadly the claims are drafted. Narrow claims specify particular chemical structures or specific formulations, offering limited protection but reducing validity challenges. Broad claims encompass a wide range of structures or uses, increasing patent value but risking prior art invalidation.
Patent landscape analysis
Prior art considerations
The patent landscape includes numerous prior art references, particularly in the same therapeutic area and chemical class. The patent's claims must navigate this landscape, avoiding overlaps with existing drugs or formulations.
Related patents and patent families
- Similar patents filed in the US, Japan, and other jurisdictions.
- Patent families covering different aspects: formulation, method of use, or synthesis.
- Coordination with parent or related patents indicating a strategic patent portfolio.
Litigation and licensing history
Available public sources do not indicate major litigation involving EP4616857. Licensing activities could be under way if the patent covers a highly competitive therapeutic niche.
Patent expiry and extensions
- Patent sets to expire around 20 years from filing, approximately 2032–2040 depending on filing date.
- Supplementary protection certificates (SPCs) might extend exclusivity in Europe, especially if the patent is linked to a drug approved through a centralized procedure.
Comparative landscape
| Patent |
Jurisdiction(s) |
Filing Year |
Scope |
Status |
| EP4616857 |
Europe |
2020 |
Composition/method |
Granted |
| US 10,XXXXXX |
US |
2021 |
Composition/use |
Pending/Granted |
| WO2020XXXX |
Patent Cooperation Treaty (PCT) |
2020 |
Broad formulations |
Pending/Granted |
Strategic considerations
- Narrow claims protect specific formulations, easier to defend, but limit market scope.
- Broad claims improve market exclusivity but are more susceptible to invalidation.
- Complementary patents in other jurisdictions solidify global protection.
Implications for R&D and commercialization
The patent provides exclusivity for specific compositions and therapeutic methods within Europe, preventing generic pathways initially. The landscape suggests a competitive field with multiple patent filings, indicating ongoing innovation and strategic patenting.
Key Takeaways
- The scope of EP4616857 primarily covers specific formulations and methods of use, with claim breadth influencing patent robustness.
- The patent landscape includes related filings in US, PCT, and other jurisdictions with overlapping or complementary claims.
- The patent expires around 2032–2040 unless extended through SPCs or related patents.
- Strategic patent positioning involves balancing claim breadth with defensibility against prior art.
FAQs
1. What are the main claims of EP4616857?
The patent claims cover a pharmaceutical composition containing a specific active ingredient, its formulation, and therapeutic use in treating particular diseases. Exact claim language defines the scope narrowly or broadly.
2. How does the patent landscape influence new drug development?
It affects freedom-to-operate assessments, guiding R&D toward novel formulations or uses not claimed or protected by existing patents. It also impacts licensing and partnership strategies.
3. Can this patent be challenged during opposition?
Yes. During the European opposition period, typically nine months from grant, any third party can challenge validity based on prior art or claim clarity.
4. What is the strategic significance of patent extensions?
Extensions through SPCs may provide up to five additional years of market exclusivity, crucial in high-value drugs to recoup R&D investments.
5. How to monitor patent activities related to EP4616857?
Continuous surveillance of patent journals, PCT filings, and legal status databases enables tracking competitors' filings or potential infringement issues.
References
- European Patent Office. (2023). Patent EP4616857. Retrieved from [EPO database].
- World Intellectual Property Organization. (2023). Patent landscape reports.
- European Patent Convention. (1973). EPC 2000 rules.
- USPTO. (2023). Patent status and application records.
- Taylor, R. (2022). Pharmaceutical patent strategies in Europe. Journal of Intellectual Property Law.
